article · 2025
Abstract P5-02-16: Thymidine kinase activity as a prognostic biomarker for first line CDK4/6 inhibitor efficacy in the Personalised Disease Monitoring in Metastatic Breast Cancer study
Abstract Background: There is an unmet need for biomarkers that improve prediction of treatment efficacy in metastatic breast cancer (MBC). Thymidine kinase ...
0 citationsDOI: https://doi.org/10.1158/1557-3265.sabcs24-p5-02-16